Mitchell Jackson, MD
Ophthalmology · Lake Villa, ILNPI 1902958929
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2019 at $121,082 and has fallen 53.8% since, to $55,905 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,118 payments — averaging $522.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$135K
- Oyster Point Pharma, Inc.$54K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$47K
- AbbVie$45K
- Lensar, Inc.$45K
- Ocular Therapeutix, Inc.$35K
- plus $222K from 37 others
Across 77 payments — averaging $10,916 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$303K
- Bausch Health US, LLC$184K
- Sight Sciences, Inc.$137K
- Ocular Therapeutix, Inc.$75K
- Kala Pharmaceuticals, Inc.$40K
- Johnson & Johnson Surgical Vision, Inc.$38K
- plus $64K from 5 others
What the payments were for
- Consulting fees$197,60934%
- Speaking & faculty fees$306,54052%
- Travel & lodging$32,6256%
- Food & beverage$46,9178%
- Gifts$1470%
- Entertainment$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$78,638
- XIIDRA$67,902
- TYRVAYA$52,419
- LENSAR LASER SYSTEM$44,642
- DEXTENZA$37,735
- OMIDRIA$27,382
- Crystalens Accommodating IOL (AT-52AO)$22,736
- VUITY$22,471
- enVista MX60 IOL$22,148
- CEQUA$21,496
- ARTEVO 800$19,112
- STELLARIS ELITE$18,879
- Trulign IOL$18,879
- Akreos AO IOL$18,879
- VEVYE$18,038
- DEXYCU$16,549
- STELLARIS PC$15,303
- CRYSTALENS$15,303
- AKREOS AO$15,303
- ENVISTA$15,303
How this compares
$583,901 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 67 | $23,353 |
| MieboPerfluorohexyloctane/Pf | 28 | $21,043 |
| BesivanceBesifloxacin Hcl | 63 | $13,876 |
| RestasisCyclosporine | 12 | $12,193 |
| XiidraLifitegrast | 16 | $11,341 |
| Cyclosporine | 11 | $7,821 |
| FlarexFluorometholone Acetate | 59 | $7,207 |
| IlevroNepafenac | 18 | $6,504 |
| LumiganBimatoprost | 12 | $5,601 |
| Loteprednol Etabonate | 30 | $3,043 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,969 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,700 |
| MoxifloxacinMoxifloxacin Hcl | 91 | $1,512 |
| Prednisolone Acetate | 28 | $1,453 |
| Latanoprost | 41 | $500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate, Lotemax Sm | $47,071 | $42,972171 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $135,333 | $32,38344 claims |
| AbbVieRestasis, Lumigan | $45,460 | $17,79524 claims |
| Eyevance Pharmaceuticals LLCFlarex | $5,170 | $7,20759 claims |
| NovartisIlevro | $19,645 | $6,50418 claims |
| AlconSimbrinza | $1,087 | $2,96913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Lake Villa
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.